Q1 2022 Results
Company overview
Financial performance
CRM
Immunology
Financial review
Neuroscience
2022 priorities
Appendix
References
Innovation: Pipeline overview
Innovation: Clinical trials
Abbreviations
Ophthalmology
Respiratory & Allergy
Oncology: Solid Tumors
Hematology
Biosimilars
Global Health
BeovuⓇ - VEGF Inhibitor
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT03917472 KINGFISHER (CRTH258B2305)
Diabetic macular edema
Phase 3
500
Change in best-corrected visual acuity (BCVA) from baseline up to week 52
Brolucizumab (RTH258) 6 mg/50 μL
Aflibercept 2 mg/50 μL
Target Patients
Patients with visual impairment due to diabetic macular edema
Read-out Milestone(s)
Q3-2021 (Actual)
Publication
Publication submission planned for H1-2022
NCT04058067 KINGLET (CRTH258B2304)
Diabetic macular edema
Phase 3
263
Change in best-corrected visual acuity (BCVA)
Brolucizumab (RTH258) 6 mg/50 μL
Aflibercept 2 mg/50 μL
Chinese patients with visual impairment due to diabetic macular edema
2023
Publication planned for 2024
81 Investor Relations | Q1 2022 Results
1 NOVARTIS | Reimagining MedicineView entire presentation